Aerie Pharmaceuticals closes stock offering
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Aerie Pharmaceuticals Inc. closed an underwritten public offering of 1,395,349 common shares at $53.75 apiece for net proceeds of about $72.4 million.
The company also sold 906,858 common shares via an at-the-market program for another $50 million.
Cantor Fitzgerald & Co. acted as the sole book runner for both transactions.
